화상 연고 시장 : 시장 규모 및 점유율 산업 분석(화상 정도별, 최종 용도별, 제품별, 지역별), 전망 및 예측(2026-2033년)

The Global Burn Ointment Market is expected to reach USD 1804.7 million by 2033, growing at a CAGR of 5.9% during (2026 - 2033).

Increasing incidence of burn injuries, growing awareness of effective wound care, and rising demand for topical treatments are driving the Burn Ointment Market across hospitals, clinics, pharmacies, and home healthcare settings. Adoption is further strengthened by the need for infection prevention, faster wound healing, pain relief, reduced scarring, convenient first-aid care, expanding healthcare access, over-the-counter wound care products, antimicrobial formulations, bioactive ingredients, moisturizing properties, and clinically validated topical solutions.

Key Market Trends & Insights

• By depth of burn, Minor Burns dominated the market in 2025 with USD 495.4 million and is projected to reach USD 724.1 million by 2033, growing at a CAGR of 5.0% during (2026 - 2033).
• Full Thickness Burns is expected to grow fastest by depth of burn, registering a CAGR of 6.6% during (2026 - 2033), supported by demand for specialized antimicrobial, regenerative, and wound-bed preparation products in severe burn care.
• Partial Thickness Burns is projected to reach USD 700.6 million by 2033, growing at a CAGR of 6.5% during (2026 - 2033), driven by infection prevention, tissue healing, pain management, and reduced scarring requirements.
• By end-use, Hospitals dominated the market in 2025 with USD 549.9 million and is projected to reach USD 823.5 million by 2033, growing at a CAGR of 5.3% during (2026 - 2033).
• Clinics and Other End-use are expected to grow faster by end-use, each registering a CAGR of 6.4% during (2026 - 2033), supported by outpatient burn care, follow-up wound management, home healthcare, pharmacies, and first-aid product usage.
• By product, Topical Antibiotics dominated the market in 2025 with USD 386.3 million and is projected to reach USD 568.1 million by 2033, growing at a CAGR of 5.1% during (2026 - 2033).
• Iodine is expected to grow fastest by product, registering a CAGR of 6.6% during (2026 - 2033), while Silver is projected to reach USD 539.5 million by 2033, supported by antimicrobial wound-care applications and burn infection control.
• Regionally, North America dominated the market in 2025 with USD 415.0 million and is projected to reach USD 621.5 million by 2033, while LAMEA is expected to grow fastest with a CAGR of 7.0% during (2026 - 2033).

Growth in the Burn Ointment Market is driven by the increasing need for accessible, effective, and clinically reliable topical treatments across different burn severities and care settings. Burn ointments are becoming important first-line solutions for minor burns and supportive treatments for more complex wounds where infection control, moisture balance, pain relief, and tissue regeneration are essential. Manufacturers are focusing on multifunctional products that combine antimicrobial activity, soothing benefits, improved skin compatibility, and enhanced healing support. Rising use of first-aid kits, pharmacy-based wound care, hospital burn protocols, and outpatient wound-management practices is also expanding product utilization.

The competitive environment is moderately consolidated and innovation-driven, with pharmaceutical companies, consumer health brands, wound-care specialists, advanced dressing manufacturers, and medical technology firms competing across topical and adjacent burn-care formats. Smith+Nephew, Convatec, Molnlycke, Coloplast, Cardinal Health, and Integra strengthen the advanced wound-care and burn-management ecosystem through hydrogels, silver dressings, antimicrobial barriers, regenerative matrices, and wound-bed preparation technologies. Kenvue, Sun Pharmaceutical, and Perrigo provide more direct topical or first-aid ointment relevance through NEOSPORIN, SILVEREX, triple-antibiotic products, and pain-relieving formulations.

Drivers

• Advancements in Integrated Burn Care Pathways Enhancing Treatment Outcomes
• Rising Incidence of Burn Injuries Fuels Demand for Effective Topical Treatments
• Technological Innovations in Ointment Formulations Enhancing Therapeutic Efficacy
• Increasing Awareness and Government Initiatives Promoting Burn Prevention and Care

Restraints

• Regulatory Ambiguity and Approval Challenges
• High Production and Raw Material Costs
• Limited Consumer Awareness and Acceptance

Opportunities

• Innovations in Advanced Formulations and Targeted Delivery Systems
• Expansion Through Enhanced Access in Emerging Economies
• Integration of Digital Health Technologies for Personalized Burn Care

Challenges

• Regulatory Compliance and Approval Complexity Hindering Burn Ointment Market Expansion
• Formulation Innovation and Manufacturing Challenges Limiting Burn Ointment Effectiveness and Availability
• Economic Barriers and Market Fragmentation Restricting Adoption and Distribution of Burn Ointments

Market Share Analysis

The global Burn Ointment Market reflects a moderately consolidated and clinically differentiated competitive landscape, with participation from direct topical first-aid brands, pharmaceutical dermatology companies, advanced wound-care manufacturers, and regenerative tissue-repair specialists. Kenvue and Perrigo maintain strong relevance in consumer first-aid ointments through antibiotic and pain-relieving formulations for minor burns, while Sun Pharmaceutical participates through its SILVEREX topical cream portfolio. Smith+Nephew, Convatec, Molnlycke, Coloplast, Cardinal Health, and Integra compete more broadly through adjacent burn and wound-care technologies such as hydrogels, silver antimicrobial dressings, Hydrofiber platforms, soft silicone dressings, gelling-fiber products, and dermal regeneration matrices.

Depth of Burn Outlook

Based on Depth of Burn, the market is segmented into Minor Burns, Partial Thickness Burns, and Full Thickness Burns. The Minor Burns market dominated the Global Burn Ointment Market by Depth of Burn in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 724.1 million by 2033, growing at a CAGR of 5 % during the forecast period. The Partial Thickness Burns market is expected to witness a CAGR of 6.5% during (2026 - 2033). Additionally, The Full Thickness Burns market is expected to witness highest CAGR of 6.6% during (2026 - 2033).

Minor Burns represent the leading segment as superficial burns are frequent in household, kitchen, workplace, and recreational settings and are commonly treated with OTC topical products. These products focus on soothing discomfort, hydration, pain relief, and infection prevention. Partial Thickness Burns require more advanced topical care because they involve deeper skin injury, blistering, pain, and higher infection risk, creating demand for antimicrobial, regenerative, and moisture-retentive formulations. Full Thickness Burns require specialized hospital-centered wound care, where ointments and adjacent topical technologies support infection control, wound-bed preparation, tissue regeneration, and surgical treatment pathways.

End-use Outlook

Based on End-use, the market is segmented into Hospitals, Clinics, and Other End-use. The Hospitals market dominated the Global Burn Ointment Market by End-use in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 823.5 million by 2033, growing at a CAGR of 5.3 % during the forecast period. The Clinics market is expected to witness a CAGR of 6.4% during (2026 - 2033). Additionally, The Other End-use market is expected to witness highest CAGR of 6.4% during (2026 - 2033).

Hospitals remain the leading end-use segment because they manage moderate-to-severe burns, acute trauma cases, complex wound infections, and specialized burn-care protocols. Hospital demand is supported by burn units, emergency departments, surgical wards, and multidisciplinary wound-care teams. Clinics address mild-to-moderate burns, outpatient wound care, dressing changes, follow-up treatment, and scar-management support. Other End-use includes home care settings, pharmacies, wellness centers, community healthcare, and first-aid use, where accessibility, affordability, ease of application, and consumer trust remain key purchase factors.

Product Outlook

Based on Product, the market is segmented into Topical Antibiotics, Silver, Iodine, and Other Product. The Topical Antibiotics market dominated the Global Burn Ointment Market by Product in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 568.2 million by 2033, growing at a CAGR of 5.1 % during the forecast period. The Silver market is expected to witness a CAGR of 6.1% during (2026 - 2033). Additionally, The Iodine market is expected to witness highest CAGR of 6.6% during (2026 - 2033).

Topical Antibiotics remain the leading product category due to their role in preventing bacterial contamination and supporting first-aid treatment for superficial and partial-thickness burns. Silver-based products are widely used for their broad antimicrobial effectiveness, especially in more complex burn and wound-care settings. Iodine-based products serve selective antiseptic applications where rapid microbial control is required. Other Product includes herbal-based formulations, honey-based gels, growth-factor products, collagen creams, bioengineered formulations, and advanced topical technologies that support scar reduction, tissue regeneration, and personalized burn recovery.

Regional Outlook

Region-wise, the Burn Ointment Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America market dominated the Global Burn Ointment Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 621.5 million by 2033, growing at a CAGR of 5.3 % during the forecast period. The Asia Pacific market is expected to witness a CAGR of 6.4% during (2026 - 2033). Additionally, The Europe market is expected to witness a CAGR of 5.7% during (2026 - 2033).

North America remains the leading regional market, supported by strong awareness of burn management, established emergency and wound-care services, advanced healthcare infrastructure, and availability of branded OTC and clinical burn-care products. Europe benefits from regulated wound-care standards, developed healthcare systems, demand for natural and advanced formulations, and established use of antimicrobial topical therapies. Asia Pacific is expanding through improving healthcare infrastructure, rising burn injury incidence, growing consumer healthcare spending, increasing OTC adoption, and demand for herbal and advanced formulations. LAMEA is developing steadily as healthcare access, pharmacy distribution, burn-care awareness, and demand for affordable topical treatments improve across emerging markets.

Recent Strategies Deployed in the Market

• 2026-May: Smith+Nephew introduced RENASYS EDGE alongside ALLEVYN COMPLETE CARE at the European Wound Management Association conference, reinforcing its broader advanced wound management and chronic wound-care platform.
• Smith+Nephew launched ALLEVYN COMPLETE CARE Foam Dressing and expanded its introduction from the United States toward Europe, supporting continued development of advanced wound-care technologies.
• Convatec planned European introduction and scale-up of Aquacel ConvaFiber, its next-generation Hydrofiber dressing platform, after receiving regulatory clearance across the UK, EU, Australia, and US in 2025.
• 2026-May: Coloplast's Biatain Silicone Fit received a Vizient Innovative Technology contract following hospital expert evaluation, strengthening its broader wound-care platform around conformity, exudate management, and clinical usability.
• 2025-April: Kenvue continued promoting NEOSPORIN + Lidocaine First Aid Antibiotic Ointment as an option for minor burns, cuts, and scrapes, combining antibiotic infection protection with lidocaine-based pain relief.
• 2023-December: Kenvue introduced NEOSPORIN + Lidocaine First Aid Antibiotic Ointment with Numbing Pain Relief in the United States, addressing minor burns and wounds through a multifunctional topical first-aid formulation.

List of Key Companies Profiled

• Smith+Nephew plc
• Convatec Group Plc
• Molnlycke Health Care AB
• Kenvue Inc.
• Coloplast A/S
• Sun Pharmaceutical Industries Ltd.
• Cardinal Health, Inc.
• Perrigo Company plc
• Integra LifeSciences Holdings Corporation

Global Burn Ointment Market Report Segmentation

By Depth of Burn

• Minor Burns
• Partial Thickness Burns
• Full Thickness Burns

By End-use

• Hospitals
• Clinics
• Other End-use

By Product

• Topical Antibiotics
• Silver
• Iodine
• Other Product

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Research Scope & Methodology

• 1.1 Market Definition
• 1.2 Analysis Period & Currency
• 1.3 Segmentation
• 1.4 Burn Ointment Market, by Geography
• 1.5 Research Methodology

Chapter 2. Market Overview

• 2.1 COVID-19 Impact
• 2.2 Market Composition and Scenario

Chapter 3. Key Factors Impacting Market

• 3.1 Market Drivers
• 3.2 Market Restraints
• 3.3 Market Opportunities
• 3.4 Market Challenges
• 3.5 Market Trends
• 3.6 State of Competition
• 3.7 Market Consolidation
• 3.8 Key Customer Criteria

Chapter 4. Product Life Cycle

Chapter 5. Value Chain Analysis of Burn Ointment Market

Chapter 6. Competition Analysis - Global

• 6.1 Market Share Analysis
• 6.2 Recent Developments
  • 6.2.1 Product Launch & Product Expansion

Chapter 7. Segmentation By Depth of Burn

• 7.1 Minor Burns
• 7.2 Partial Thickness Burns
• 7.3 Full Thickness Burns

Chapter 8. Segmentation By End-use

• 8.1 Hospitals
• 8.2 Clinics
• 8.3 Other End-use

Chapter 9. Segmentation By Product

• 9.1 Topical Antibiotics
• 9.2 Silver
• 9.3 Iodine
• 9.4 Other Products

Chapter 10. North America Market

• 10.1 Market Overview
• 10.2 Key Factors Impacting Market
  • 10.2.1 Market Drivers
  • 10.2.2 Market Restraints
  • 10.2.3 Market Opportunities
  • 10.2.4 Market Challenges
  • 10.2.5 Market Trends
  • 10.2.6 State of Competition
  • 10.2.7 Market Consolidation
  • 10.2.8 Key Customer Criteria
• 10.3 Product Life Cycle
• 10.4 Segmentation By Depth of Burn
  • 10.4.1 Minor Burns
  • 10.4.2 Partial Thickness Burns
  • 10.4.3 Full Thickness Burns
• 10.5 Segmentation By End-use
  • 10.5.1 Hospitals
  • 10.5.2 Clinics
  • 10.5.3 Other End-use
• 10.6 Segmentation By Product
  • 10.6.1 Topical Antibiotics
  • 10.6.2 Silver
  • 10.6.3 Iodine
  • 10.6.4 Other Product
• 10.7 Segmentation By Country
  • 10.7.1 US
    • 10.7.1.1 Segmentation By Depth of Burn
      • 10.7.1.1.1 Minor Burns
      • 10.7.1.1.2 Partial Thickness Burns
      • 10.7.1.1.3 Full Thickness Burns
    • 10.7.1.2 Segmentation By End-use
      • 10.7.1.2.1 Hospitals
      • 10.7.1.2.2 Clinics
      • 10.7.1.2.3 Other End-use
    • 10.7.1.3 Segmentation By Product
      • 10.7.1.3.1 Topical Antibiotics
      • 10.7.1.3.2 Silver
      • 10.7.1.3.3 Iodine
      • 10.7.1.3.4 Other Product
  • 10.7.2 Canada
    • 10.7.2.1 Segmentation By Depth of Burn
      • 10.7.2.1.1 Minor Burns
      • 10.7.2.1.2 Partial Thickness Burns
      • 10.7.2.1.3 Full Thickness Burns
    • 10.7.2.2 Segmentation By End-use
      • 10.7.2.2.1 Hospitals
      • 10.7.2.2.2 Clinics
      • 10.7.2.2.3 Other End-use
    • 10.7.2.3 Segmentation By Product
      • 10.7.2.3.1 Topical Antibiotics
      • 10.7.2.3.2 Silver
      • 10.7.2.3.3 Iodine
      • 10.7.2.3.4 Other Product
  • 10.7.3 Mexico
    • 10.7.3.1 Segmentation By Depth of Burn
      • 10.7.3.1.1 Minor Burns
      • 10.7.3.1.2 Partial Thickness Burns
      • 10.7.3.1.3 Full Thickness Burns
    • 10.7.3.2 Segmentation By End-use
      • 10.7.3.2.1 Hospitals
      • 10.7.3.2.2 Clinics
      • 10.7.3.2.3 Other End-use
    • 10.7.3.3 Segmentation By Product
      • 10.7.3.3.1 Topical Antibiotics
      • 10.7.3.3.2 Silver
      • 10.7.3.3.3 Iodine
      • 10.7.3.3.4 Other Product
  • 10.7.4 Rest of North America
    • 10.7.4.1 Segmentation By Depth of Burn
      • 10.7.4.1.1 Minor Burns
      • 10.7.4.1.2 Partial Thickness Burns
      • 10.7.4.1.3 Full Thickness Burns
    • 10.7.4.2 Segmentation By End-use
      • 10.7.4.2.1 Hospitals
      • 10.7.4.2.2 Clinics
      • 10.7.4.2.3 Other End-use
    • 10.7.4.3 Segmentation By Product
      • 10.7.4.3.1 Topical Antibiotics
      • 10.7.4.3.2 Silver
      • 10.7.4.3.3 Iodine
      • 10.7.4.3.4 Other Product

Chapter 11. Europe Market

• 11.1 Market Overview
• 11.2 Key Factors Impacting Market
  • 11.2.1 Market Drivers
  • 11.2.2 Market Restraints
  • 11.2.3 Market Opportunities
  • 11.2.4 Market Challenges
  • 11.2.5 Market Trends
  • 11.2.6 State of Competition
  • 11.2.7 Market Consolidation
  • 11.2.8 Key Customer Criteria
• 11.3 Product Life Cycle
• 11.4 Segmentation By Depth of Burn
  • 11.4.1 Minor Burns
  • 11.4.2 Partial Thickness Burns
  • 11.4.3 Full Thickness Burns
• 11.5 Segmentation By End-use
  • 11.5.1 Hospitals
  • 11.5.2 Clinics
  • 11.5.3 Other End-use
• 11.6 Segmentation By Product
  • 11.6.1 Topical Antibiotics
  • 11.6.2 Silver
  • 11.6.3 Iodine
  • 11.6.4 Other Products
• 11.7 Segmentation By Country
  • 11.7.1 Germany
    • 11.7.1.1 Segmentation By Depth of Burn
      • 11.7.1.1.1 Minor Burns
      • 11.7.1.1.2 Partial Thickness Burns
      • 11.7.1.1.3 Full Thickness Burns
    • 11.7.1.2 Segmentation By End-use
      • 11.7.1.2.1 Hospitals
      • 11.7.1.2.2 Clinics
      • 11.7.1.2.3 Other End-use
    • 11.7.1.3 Segmentation By Product
      • 11.7.1.3.1 Topical Antibiotics
      • 11.7.1.3.2 Silver
      • 11.7.1.3.3 Iodine
      • 11.7.1.3.4 Other Product
  • 11.7.2 UK
    • 11.7.2.1 Segmentation By Depth of Burn
      • 11.7.2.1.1 Minor Burns
      • 11.7.2.1.2 Partial Thickness Burns
      • 11.7.2.1.3 Full Thickness Burns
    • 11.7.2.2 Segmentation By End-use
      • 11.7.2.2.1 Hospitals
      • 11.7.2.2.2 Clinics
      • 11.7.2.2.3 Other End-use
    • 11.7.2.3 Segmentation By Product
      • 11.7.2.3.1 Topical Antibiotics
      • 11.7.2.3.2 Silver
      • 11.7.2.3.3 Iodine
      • 11.7.2.3.4 Other Product
  • 11.7.3 France
    • 11.7.3.1 Segmentation By Depth of Burn
      • 11.7.3.1.1 Minor Burns
      • 11.7.3.1.2 Partial Thickness Burns
      • 11.7.3.1.3 Full Thickness Burns
    • 11.7.3.2 Segmentation By End-use
      • 11.7.3.2.1 Hospitals
      • 11.7.3.2.2 Clinics
      • 11.7.3.2.3 Other End-use
    • 11.7.3.3 Segmentation By Product
      • 11.7.3.3.1 Topical Antibiotics
      • 11.7.3.3.2 Silver
      • 11.7.3.3.3 Iodine
      • 11.7.3.3.4 Other Product
  • 11.7.4 Russia
    • 11.7.4.1 Segmentation By Depth of Burn
      • 11.7.4.1.1 Minor Burns
      • 11.7.4.1.2 Partial Thickness Burns
      • 11.7.4.1.3 Full Thickness Burns
    • 11.7.4.2 Segmentation By End-use
      • 11.7.4.2.1 Hospitals
      • 11.7.4.2.2 Clinics
      • 11.7.4.2.3 Other End-use
    • 11.7.4.3 Segmentation By Product
      • 11.7.4.3.1 Topical Antibiotics
      • 11.7.4.3.2 Silver
      • 11.7.4.3.3 Iodine
      • 11.7.4.3.4 Other Product
  • 11.7.5 Spain
    • 11.7.5.1 Segmentation By Depth of Burn
      • 11.7.5.1.1 Minor Burns
      • 11.7.5.1.2 Partial Thickness Burns
      • 11.7.5.1.3 Full Thickness Burns
    • 11.7.5.2 Segmentation By End-use
      • 11.7.5.2.1 Hospitals
      • 11.7.5.2.2 Clinics
      • 11.7.5.2.3 Other End-use
    • 11.7.5.3 Segmentation By Product
      • 11.7.5.3.1 Topical Antibiotics
      • 11.7.5.3.2 Silver
      • 11.7.5.3.3 Iodine
      • 11.7.5.3.4 Other Product
  • 11.7.6 Italy
    • 11.7.6.1 Segmentation By Depth of Burn
      • 11.7.6.1.1 Minor Burns
      • 11.7.6.1.2 Partial Thickness Burns
      • 11.7.6.1.3 Full Thickness Burns
    • 11.7.6.2 Segmentation By End-use
      • 11.7.6.2.1 Hospitals
      • 11.7.6.2.2 Clinics
      • 11.7.6.2.3 Other End-use
    • 11.7.6.3 Segmentation By Product
      • 11.7.6.3.1 Topical Antibiotics
      • 11.7.6.3.2 Silver
      • 11.7.6.3.3 Iodine
      • 11.7.6.3.4 Other Product
  • 11.7.7 Rest of Europe
    • 11.7.7.1 Segmentation By Depth of Burn
      • 11.7.7.1.1 Minor Burns
      • 11.7.7.1.2 Partial Thickness Burns
      • 11.7.7.1.3 Full Thickness Burns
    • 11.7.7.2 Segmentation By End-use
      • 11.7.7.2.1 Hospitals
      • 11.7.7.2.2 Clinics
      • 11.7.7.2.3 Other End-use
    • 11.7.7.3 Segmentation By Product
      • 11.7.7.3.1 Topical Antibiotics
      • 11.7.7.3.2 Silver
      • 11.7.7.3.3 Iodine
      • 11.7.7.3.4 Other Product

Chapter 12. Asia Pacific Market

• 12.1 Market Overview
• 12.2 Key Factors Impacting Market
  • 12.2.1 Market Drivers
  • 12.2.2 Market Restraints
  • 12.2.3 Market Opportunities
  • 12.2.4 Market Challenges
  • 12.2.5 Market Trends
  • 12.2.6 State of Competition
  • 12.2.7 Market Consolidation
  • 12.2.8 Key Customer Criteria
• 12.3 Product Life Cycle
• 12.4 Segmentation By Depth of Burn
  • 12.4.1 Minor Burns
  • 12.4.2 Partial Thickness Burns
  • 12.4.3 Full Thickness Burns
• 12.5 Segmentation By End-use
  • 12.5.1 Hospitals
  • 12.5.2 Clinics
  • 12.5.3 Other End-use
• 12.6 Segmentation By Product
  • 12.6.1 Topical Antibiotics
  • 12.6.2 Silver
  • 12.6.3 Iodine
  • 12.6.4 Other Product
• 12.7 Segmentation By Country
  • 12.7.1 China
    • 12.7.1.1 Segmentation By Depth of Burn
      • 12.7.1.1.1 Minor Burns
      • 12.7.1.1.2 Partial Thickness Burns
      • 12.7.1.1.3 Full Thickness Burns
    • 12.7.1.2 Segmentation By End-use
      • 12.7.1.2.1 Hospitals
      • 12.7.1.2.2 Clinics
      • 12.7.1.2.3 Other End-use
    • 12.7.1.3 Segmentation By Product
      • 12.7.1.3.1 Topical Antibiotics
      • 12.7.1.3.2 Silver
      • 12.7.1.3.3 Iodine
      • 12.7.1.3.4 Other Product
  • 12.7.2 Japan
    • 12.7.2.1 Segmentation By Depth of Burn
      • 12.7.2.1.1 Minor Burns
      • 12.7.2.1.2 Partial Thickness Burns
      • 12.7.2.1.3 Full Thickness Burns
    • 12.7.2.2 Segmentation By End-use
      • 12.7.2.2.1 Hospitals
      • 12.7.2.2.2 Clinics
      • 12.7.2.2.3 Other End-use
    • 12.7.2.3 Segmentation By Product
      • 12.7.2.3.1 Topical Antibiotics
      • 12.7.2.3.2 Silver
      • 12.7.2.3.3 Iodine
      • 12.7.2.3.4 Other Product
  • 12.7.3 India
    • 12.7.3.1 Segmentation By Depth of Burn
      • 12.7.3.1.1 Minor Burns
      • 12.7.3.1.2 Partial Thickness Burns
      • 12.7.3.1.3 Full Thickness Burns
    • 12.7.3.2 Segmentation By End-use
      • 12.7.3.2.1 Hospitals
      • 12.7.3.2.2 Clinics
      • 12.7.3.2.3 Other End-use
    • 12.7.3.3 Segmentation By Product
      • 12.7.3.3.1 Topical Antibiotics
      • 12.7.3.3.2 Silver
      • 12.7.3.3.3 Iodine
      • 12.7.3.3.4 Other Product
  • 12.7.4 South Korea
    • 12.7.4.1 Segmentation By Depth of Burn
      • 12.7.4.1.1 Minor Burns
      • 12.7.4.1.2 Partial Thickness Burns
      • 12.7.4.1.3 Full Thickness Burns
    • 12.7.4.2 Segmentation By End-use
      • 12.7.4.2.1 Hospitals
      • 12.7.4.2.2 Clinics
      • 12.7.4.2.3 Other End-use
    • 12.7.4.3 Segmentation By Product
      • 12.7.4.3.1 Topical Antibiotics
      • 12.7.4.3.2 Silver
      • 12.7.4.3.3 Iodine
      • 12.7.4.3.4 Other Product
  • 12.7.5 Singapore
    • 12.7.5.1 Segmentation By Depth of Burn
      • 12.7.5.1.1 Minor Burns
      • 12.7.5.1.2 Partial Thickness Burns
      • 12.7.5.1.3 Full Thickness Burns
    • 12.7.5.2 Segmentation By End-use
      • 12.7.5.2.1 Hospitals
      • 12.7.5.2.2 Clinics
      • 12.7.5.2.3 Other End-use
    • 12.7.5.3 Segmentation By Product
      • 12.7.5.3.1 Topical Antibiotics
      • 12.7.5.3.2 Silver
      • 12.7.5.3.3 Iodine
      • 12.7.5.3.4 Other Product
  • 12.7.6 Malaysia
    • 12.7.6.1 Segmentation By Depth of Burn
      • 12.7.6.1.1 Minor Burns
      • 12.7.6.1.2 Partial Thickness Burns
      • 12.7.6.1.3 Full Thickness Burns
    • 12.7.6.2 Segmentation By End-use
      • 12.7.6.2.1 Hospitals
      • 12.7.6.2.2 Clinics
      • 12.7.6.2.3 Other End-use
    • 12.7.6.3 Segmentation By Product
      • 12.7.6.3.1 Topical Antibiotics
      • 12.7.6.3.2 Silver
      • 12.7.6.3.3 Iodine
      • 12.7.6.3.4 Other Product
  • 12.7.7 Rest of Asia Pacific
    • 12.7.7.1 Segmentation By Depth of Burn
      • 12.7.7.1.1 Minor Burns
      • 12.7.7.1.2 Partial Thickness Burns
      • 12.7.7.1.3 Full Thickness Burns
    • 12.7.7.2 Segmentation By End-use
      • 12.7.7.2.1 Hospitals
      • 12.7.7.2.2 Clinics
      • 12.7.7.2.3 Other End-use
    • 12.7.7.3 Segmentation By Product
      • 12.7.7.3.1 Topical Antibiotics
      • 12.7.7.3.2 Silver
      • 12.7.7.3.3 Iodine
      • 12.7.7.3.4 Other Product

Chapter 13. LAMEA Market

• 13.1 Market Overview
• 13.2 Key Factors Impacting Market
  • 13.2.1 Market Drivers
  • 13.2.2 Market Restraints
  • 13.2.3 Market Opportunities
  • 13.2.4 Market Challenges
  • 13.2.5 Market Trends
  • 13.2.6 State of Competition
  • 13.2.7 Market Consolidation
  • 13.2.8 Key Customer Criteria
• 13.3 Product Life Cycle
• 13.4 Segmentation By Depth of Burn
  • 13.4.1 Minor Burns
  • 13.4.2 Partial Thickness Burns
  • 13.4.3 Full Thickness Burns
• 13.5 Segmentation By End-use
  • 13.5.1 Hospitals
  • 13.5.2 Clinics
  • 13.5.3 Other End-use
• 13.6 Segmentation By Product
  • 13.6.1 Topical Antibiotics
  • 13.6.2 Silver
  • 13.6.3 Iodine
  • 13.6.4 Other End-use
• 13.7 Segmentation By Country
  • 13.7.1 Brazil
    • 13.7.1.1 Segmentation By Depth of Burn
      • 13.7.1.1.1 Minor Burns
      • 13.7.1.1.2 Partial Thickness Burns
      • 13.7.1.1.3 Full Thickness Burns
    • 13.7.1.2 Segmentation By End-use
      • 13.7.1.2.1 Hospitals
      • 13.7.1.2.2 Clinics
      • 13.7.1.2.3 Other End-use
    • 13.7.1.3 Segmentation By Product
      • 13.7.1.3.1 Topical Antibiotics
      • 13.7.1.3.2 Silver
      • 13.7.1.3.3 Iodine
      • 13.7.1.3.4 Other Product
  • 13.7.2 Argentina
    • 13.7.2.1 Segmentation By Depth of Burn
      • 13.7.2.1.1 Minor Burns
      • 13.7.2.1.2 Partial Thickness Burns
      • 13.7.2.1.3 Full Thickness Burns
    • 13.7.2.2 Segmentation By End-use
      • 13.7.2.2.1 Hospitals
      • 13.7.2.2.2 Clinics
      • 13.7.2.2.3 Other End-use
    • 13.7.2.3 Segmentation By Product
      • 13.7.2.3.1 Topical Antibiotics
      • 13.7.2.3.2 Silver
      • 13.7.2.3.3 Iodine
      • 13.7.2.3.4 Other Product
  • 13.7.3 UAE
    • 13.7.3.1 Segmentation By Depth of Burn
      • 13.7.3.1.1 Minor Burns
      • 13.7.3.1.2 Partial Thickness Burns
      • 13.7.3.1.3 Full Thickness Burns
    • 13.7.3.2 Segmentation By End-use
      • 13.7.3.2.1 Hospitals
      • 13.7.3.2.2 Clinics
      • 13.7.3.2.3 Other End-use
    • 13.7.3.3 Segmentation By Product
      • 13.7.3.3.1 Topical Antibiotics
      • 13.7.3.3.2 Silver
      • 13.7.3.3.3 Iodine
      • 13.7.3.3.4 Other Product
  • 13.7.4 Saudi Arabia
    • 13.7.4.1 Segmentation By Depth of Burn
      • 13.7.4.1.1 Minor Burns
      • 13.7.4.1.2 Partial Thickness Burns
      • 13.7.4.1.3 Full Thickness Burns
    • 13.7.4.2 Segmentation By End-use
      • 13.7.4.2.1 Hospitals
      • 13.7.4.2.2 Clinics
      • 13.7.4.2.3 Other End-use
    • 13.7.4.3 Segmentation By Product
      • 13.7.4.3.1 Topical Antibiotics
      • 13.7.4.3.2 Silver
      • 13.7.4.3.3 Iodine
      • 13.7.4.3.4 Other Product
  • 13.7.5 South Africa
    • 13.7.5.1 Segmentation By Depth of Burn
      • 13.7.5.1.1 Minor Burns
      • 13.7.5.1.2 Partial Thickness Burns
      • 13.7.5.1.3 Full Thickness Burns
    • 13.7.5.2 Segmentation By End-use
      • 13.7.5.2.1 Hospitals
      • 13.7.5.2.2 Clinics
      • 13.7.5.2.3 Other End-use
    • 13.7.5.3 Segmentation By Product
      • 13.7.5.3.1 Topical Antibiotics
      • 13.7.5.3.2 Silver
      • 13.7.5.3.3 Iodine
      • 13.7.5.3.4 Other Product
  • 13.7.6 Nigeria
    • 13.7.6.1 Segmentation By Depth of Burn
      • 13.7.6.1.1 Minor Burns
      • 13.7.6.1.2 Partial Thickness Burns
      • 13.7.6.1.3 Full Thickness Burns
    • 13.7.6.2 Segmentation By End-use
      • 13.7.6.2.1 Hospitals
      • 13.7.6.2.2 Clinics
      • 13.7.6.2.3 Other End-use
    • 13.7.6.3 Segmentation By Product
      • 13.7.6.3.1 Topical Antibiotics
      • 13.7.6.3.2 Silver
      • 13.7.6.3.3 Iodine
      • 13.7.6.3.4 Other Product
  • 13.7.7 Rest of LAMEA
    • 13.7.7.1 Segmentation By Depth of Burn
      • 13.7.7.1.1 Minor Burns
      • 13.7.7.1.2 Partial Thickness Burns
      • 13.7.7.1.3 Full Thickness Burns
    • 13.7.7.2 Segmentation By End-use
      • 13.7.7.2.1 Hospitals
      • 13.7.7.2.2 Clinics
      • 13.7.7.2.3 Other End-use
    • 13.7.7.3 Segmentation By Product
      • 13.7.7.3.1 Topical Antibiotics
      • 13.7.7.3.2 Silver
      • 13.7.7.3.3 Iodine
      • 13.7.7.3.4 Other Product

Chapter 14. Company Snapshots

• 14.1 Smith+Nephew plc
  • 14.1.1 Business Overview
  • 14.1.2 Key Information
  • 14.1.3 Company Focus on Burn Ointment Market
  • 14.1.4 Strategic Insights
  • 14.1.5 Strategy Deployed
  • 14.1.6 Product & Service Portfolio
  • 14.1.7 Capability Overview
  • 14.1.8 Technology & Innovation Focus
  • 14.1.9 SWOT
  • 14.1.10 Customers / End Users
  • 14.1.11 Competitive Positioning
  • 14.1.12 Key Differentiators
  • 14.1.13 Portfolio Matrix
  • 14.1.14 Future Outlook
• 14.2 Convatec Group Plc
  • 14.2.1 Business Overview
  • 14.2.2 Key Information
  • 14.2.3 Company Focus on Burn Ointment Market
  • 14.2.4 Strategic Insights
  • 14.2.5 Strategy Deployed
  • 14.2.6 Product & Service Portfolio
  • 14.2.7 Capability Overview
  • 14.2.8 Technology & Innovation Focus
  • 14.2.9 SWOT Analysis
  • 14.2.10 Customers / End Users
  • 14.2.11 Competitive Positioning
  • 14.2.12 Key Differentiators
  • 14.2.13 Portfolio Matrix
  • 14.2.14 Future Outlook
• 14.3 Molnlycke Health Care AB
  • 14.3.1 Business Overview
  • 14.3.2 Key Information
  • 14.3.3 Company Focus on Burn Ointment Market
  • 14.3.4 Strategic Insights
  • 14.3.5 Strategy Deployed
  • 14.3.6 Product & Service Portfolio
  • 14.3.7 Capability Overview
  • 14.3.8 Technology & Innovation Focus
  • 14.3.9 SWOT Analysis
  • 14.3.10 Customers / End Users
  • 14.3.11 Competitive Positioning
  • 14.3.12 Key Differentiators
  • 14.3.13 Portfolio Matrix
  • 14.3.14 Future Outlook
• 14.4 Kenvue Inc.
  • 14.4.1 Business Overview
  • 14.4.2 Key Information
  • 14.4.3 Company Focus on Burn Ointment Market
  • 14.4.4 Strategic Insights
  • 14.4.5 Strategy Deployed
  • 14.4.6 Product & Service Portfolio
  • 14.4.7 Capability Overview
  • 14.4.8 Technology & Innovation Focus
  • 14.4.9 SWOT Analysis
  • 14.4.10 Customers / End Users
  • 14.4.11 Competitive Positioning
  • 14.4.12 Key Differentiators
  • 14.4.13 Portfolio Matrix
  • 14.4.14 Future Outlook
• 14.5 Coloplast A/S
  • 14.5.1 Business Overview
  • 14.5.2 Key Information
  • 14.5.3 Company Focus on Burn Ointment Market
  • 14.5.4 Strategic Insights
  • 14.5.5 Strategy Deployed
  • 14.5.6 Product & Service Portfolio
  • 14.5.7 Capability Overview
  • 14.5.8 Technology & Innovation Focus
  • 14.5.9 SWOT Analysis
  • 14.5.10 Customers / End Users
  • 14.5.11 Competitive Positioning
  • 14.5.12 Key Differentiators
  • 14.5.13 Portfolio Matrix
  • 14.5.14 Future Outlook
• 14.6 Sun Pharmaceutical Industries Ltd.
  • 14.6.1 Business Overview
  • 14.6.2 Key Information
  • 14.6.3 Company Focus on Burn Ointment Market
  • 14.6.4 Strategic Insights
  • 14.6.5 Strategy Deployed
  • 14.6.6 Product & Service Portfolio
  • 14.6.7 Capability Overview
  • 14.6.8 Technology & Innovation Focus
  • 14.6.9 SWOT Analysis
  • 14.6.10 Customers / End Users
  • 14.6.11 Competitive Positioning
  • 14.6.12 Key Differentiators
  • 14.6.13 Portfolio Matrix
  • 14.6.14 Future Outlook
• 14.7 Cardinal Health, Inc.
  • 14.7.1 Business Overview
  • 14.7.2 Key Information
  • 14.7.3 Company Focus on Burn Ointment Market
  • 14.7.4 Strategic Insights
  • 14.7.5 Strategy Deployed
  • 14.7.6 Product & Service Portfolio
  • 14.7.7 Capability Overview
  • 14.7.8 Technology & Innovation Focus
  • 14.7.9 SWOT Analysis
  • 14.7.10 Customers / End Users
  • 14.7.11 Competitive Positioning
  • 14.7.12 Key Differentiators
  • 14.7.13 Portfolio Matrix
  • 14.7.14 Future Outlook
• 14.8 Perrigo Company plc
  • 14.8.1 Business Overview
  • 14.8.2 Key Information
  • 14.8.3 Company Focus on Burn Ointment Market
  • 14.8.4 Strategic Insights
  • 14.8.5 Strategy Deployed
  • 14.8.6 Product & Service Portfolio
  • 14.8.7 Capability Overview
  • 14.8.8 Technology & Innovation Focus
  • 14.8.9 SWOT Analysis
  • 14.8.10 Customers / End Users
  • 14.8.11 Competitive Positioning
  • 14.8.12 Key Differentiators
  • 14.8.13 Portfolio Matrix
  • 14.8.14 Future Outlook
• 14.9 Integra LifeSciences Holdings Corporation
  • 14.9.1 Business Overview
  • 14.9.2 Key Information
  • 14.9.3 Company Focus on Burn Ointment Market
  • 14.9.4 Strategic Insights
  • 14.9.5 Strategy Deployed
  • 14.9.6 Product & Service Portfolio
  • 14.9.7 Capability Overview
  • 14.9.8 Technology & Innovation Focus
  • 14.9.9 SWOT Analysis
  • 14.9.10 Customers / End Users
  • 14.9.11 Competitive Positioning
  • 14.9.12 Key Differentiators
  • 14.9.13 Portfolio Matrix
  • 14.9.14 Future Outlook

Chapter 15. Winning Imperatives of Burn Ointment Market